IDRI awarded $1.8M contract to develop adjuvant formulations for pandemic influenza

The Infectious Disease Research Institute (IDRI) has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority (BARDA). IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency.

"BARDA is supporting an important expansion of IDRI's technology to solutions that address Neglected Diseases as well as those that affect us all in the United States," says Dr. Darrick Carter, Director of Formulations at IDRI and Principal Investigator on the BARDA influenza contract. Adjuvants and other immunostimulants can improve the body's immune response to diseases like influenza, in turn, reducing the amount of vaccine needed for protection (dose-sparing). The use of adjuvants will allow for expansion of vaccine supply to meet the necessary global demands during a pandemic.

BARDA is within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The project is part of the innovations portfolio awarded out of BARDA's Strategic Science and Technology Division's Innovation BAA (Broad Agency Announcement).

Source:

Infectious Disease Research Institute (IDRI)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thousands could have been saved during the pandemic with expanded use of convalescent plasma